Meningococcal meningitis outbreaks occur during the dry season in the African meningitis belt and cause hundreds of thousands deaths every year. PsA-TT vaccine (MenAfriVac®) has been developed specifically to tackle serogroup A meningococci, the main causative strain of outbreaks. A PsA-TT mass campaign was launched in Burkina Faso in 2010.
AMP's antibody persistence study aims to describe population immunity following vaccine introduction in Burkina Faso, using serogroup-specific serum bactericidal antibody titers and serum IgG antibody concentrations as indicators. Three surveys (2011, 2013 and 2015) evaluate vaccine coverage among 600 subjects randomly picked in the population of Bobo-Dioulasso, aged from 6 months to 29 and enrolled at home. Study visits including blood draws will take place at the Centre Muraz in Bobo-Dioulasso.
The first survey was conducted in November 2011 and sera analyses are ongoing. Part of the serological analyses will be done in the study country. The measure of IgG antibody concentrations will be performed at Centre Muraz following a technology transfer with technical support from the Center for Vaccine Development (CVD) and the London School of Hygiene and Tropical Medicine (LSHTM).